Please assess the completion status of the following clinical trial:

Trial Title: Islet Transplantation for Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Have had Type 1 diabetes mellitus for more than 5 years, and are exhibiting 1 of the following, despite intensive insulin management efforts: a) hypoglycemic unawareness, as defined by inability to sense hypoglycemia until the blood glucose falls to less than 54 mg/dL; b) metabolic instability, with 2 or more episodes of severe hypoglycemia (defined as an event with symptoms consistent with hypoglycemia in which the patient requires the assistance of another person and which is associated with a blood glucose below 54 mg/dL) or 2 or more hospital visits for diabetic ketoacidosis over the last year; or c) despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by retinopathy, nephropathy, or neuropathy.~* Are 18 to 65 years of age.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Have had severe cardiac disease as defined by: a) recent myocardial infarction within the past 6 months; b) angiographic evidence of non-correctable coronary artery disease; or c) evidence of ischemia on a functional cardiac exam.~* Actively abuse alcohol or substances, including cigarette smoking (must not have smoked within the last 6 months).~* Have psychiatric problems that prevent them from being a suitable candidate for transplantation (such as schizophrenia, bipolar disorder, or major depression that is not controlled or stable on current medication).~* Have a history of not following prescribed regimens.~* Have active infection including hepatitis C virus, hepatitis B virus, human immunodeficiency virus (HIV), or Tuberculosis (TB) (or under treatment for suspected TB).~* Have a history of malignancy, except squamous or basal skin cancer.~* Weigh more than 70 kilograms or have a Body Mass Index (BMI) greater than 26 kg/m\^2 at time of screening.~* Have a C-peptide value of 0.3 ng/ml or more following a 5.0 gram intravenous arginine infusion challenge.~* Are unable to provide informed consent.~* Have gallstones or hemangioma in liver.~* Have untreated proliferative retinopathy.~* Are breast-feeding or pregnant, or intend to try and become pregnant (females) or to father a child (males), or fail to follow birth control methods.~* Have had a previous transplant, or evidence of anti-human leukocyte antigen (HLA) antibody.~* Have an insulin requirement of more that 0.7 International Units (IU)/kilograms/day.~* Have a blood glycosylated hemoglobin (HbA1c) higher than 12 percent.~* Are unable to reach the hospital for transplantation within 2 hours of notification.~* Have untreated or treated hyperlipidemia.~* Have a medical condition requiring chronic use of steroids.~* Use coumadin or other anticoagulants (aspirin is allowed).~* Have Addison's disease.~* Have a negative screen for Epstein-Barr virus (EBV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Islet Transplantation (Type: EXPERIMENTAL): All study participants

Based on this trial design, predict the completion outcome and termination type (if applicable).